High Risk Research: HHS Should Publicly Share More Information on How Risk Is Assessed and Mitigated
The Government Accountability Office (GAO) reports that the Department of Health and Human Services (HHS) conducts risk assessments for gain‑of‑function research but does not consistently share those findings with the public. While the research has expanded understanding of pathogen transmission, its direct contribution to vaccines such as those for COVID‑19 remains disputed. GAO notes broad consensus that such work carries biosafety and biosecurity risks, and that greater transparency could bolster public trust. Recent legislative and executive actions aim to restrict or ban high‑risk pathogen studies.
Oral Nanozyme Treats Colitis-Linked Mental Disorders via Gut-Brain Axis
Researchers at Yangzhou and Nanjing Universities have created an oral polysaccharide‑engineered nanozyme—fucoidan‑cerium nanocomplexes (FucCeNCs)—to treat colitis‑associated anxiety and depression. The nanocomplex combines cerium’s superoxide dismutase‑like activity with fucoidan’s prebiotic properties, enabling simultaneous reactive oxygen/nitrogen species scavenging and gut microbiota modulation....
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics shares rose over 12% after reporting Q4 2025 earnings that showed a larger‑than‑expected loss and minimal recognized revenue. The company’s flagship therapy CASGEVY generated $54 million in sales, but under its revenue‑sharing deal with Vertex only $0.86 million was recorded. CRISPR...
STAT+: What to Expect From Gossamer Bio’s Late-Stage Lung Disease Study
Gossamer Bio is set to announce results from its Phase 3 trial in pulmonary arterial hypertension (PAH) before the end of February. The readout follows a Phase 2 study that delivered modest, sub‑par efficacy, which the company attributes to an...
Partial Reprogramming of Neurons Encoding Memory Improves Cognitive Function in Aged Mice
Researchers applied cyclic OSK (Oct4‑Sox2‑Klf4) gene therapy to memory‑encoding neurons in aged mice, achieving partial cellular reprogramming without full pluripotency. The intervention reversed senescence‑related gene expression, restored youthful epigenetic patterns, and normalized synaptic plasticity in both hippocampal and prefrontal engrams....
Pharma Pulse: FDA’s Moderna Reversal and Eli Lilly’s $100 Million IL-6 Bet
The FDA has reversed its earlier refusal-to-file and will review Moderna’s seasonal mRNA influenza vaccine, with a decision slated for August 5, 2026. Moderna now seeks full approval for adults aged 50‑64 and accelerated approval for those 65 and older. Meanwhile, Eli Lilly...
Antioxidant Nanoparticles May Protect Male Fertility During Chemotherapy
A preclinical study published in Reproductive and Developmental Medicine found that combining melatonin with zinc oxide nanoparticles mitigates cyclophosphamide‑induced reproductive toxicity in male rats. The antioxidant duo restored testosterone and luteinizing hormone levels, lowered oxidative stress markers, and preserved spermatogenic...
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck (MSD) and Mayo Clinic have launched a research partnership that blends Mayo's Platform architecture and multimodal clinical‑genomic data with MSD's virtual‑cell technologies. The collaboration gives MSD direct access to de‑identified imaging, lab, molecular and notes data to train and...
MSD and Mayo Clinic Team up to Advance AI in Drug Development
Merck & Co (MSD) and Mayo Clinic have launched a research partnership that leverages AI, advanced analytics, and multimodal clinical‑genomic data to accelerate drug discovery and precision medicine. The collaboration merges Mayo’s Platform architecture and de‑identified datasets—including imaging, labs, molecular...
Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets
Alphabet’s Verily has introduced a free, self‑serve Standard tier for its Pre precision‑health platform, allowing researchers to access the Exchange catalog and Workbench environment with just a Google account. The rollout adds three high‑impact datasets: a single‑cell AML cohort from...
UV Red Flag: Color-Changing ‘Living’ Material Warns of Harmful Radiation
Researchers at the Technical University of Munich have created a bio‑hybrid coating that visibly signals UV‑A exposure by turning from green to red. The sensor embeds dry Escherichia coli cells loaded with the photoconvertible protein mEosFP, which undergoes an irreversible...
Gold@MnFe‐Prussian Blue Analog Yolk@Shell Nanoparticles for Light‐Triggered and pH‐Sensitive Drug Release
Researchers have engineered Au@MnFe‑Prussian Blue Analog yolk‑shell nanoparticles that combine a hollow cavity with a functional shell for biomedical use. The synthesis creates a ~75 nm interior, achieving roughly 50% loading efficiency for the chemotherapeutic doxorubicin. Partial etching and redeposition of...
Achieving High‐Efficiency Type I Multimodal Photosensitizers via a Synergistic Rigidity‐Flexibility Strategy for Hypoxia‐Resistant Tumor Therapy
Researchers introduced a donor‑acceptor (D‑A) molecular design that couples a rigid coplanar backbone with flexible side chains, dramatically raising near‑infrared molar extinction and fluorescence brightness. The resulting phenothiazine‑based photosensitizer, EL‑TPO2F, also exhibits strong type‑I reactive oxygen species (ROS) production and...
Swedish CubaseBio Emerges From Stealth with €5.9 Million to Scale Volumetric DNA Microscopy
Swedish startup CubaseBio has emerged from stealth after raising €5.9 million in blended financing – a €2 million European Innovation Council grant plus €3.9 million from Voima Ventures, Nordic Science Investments, Illumina Ventures and other life‑science investors. The capital will accelerate development of...
9 Companies Hiring Now in Pennsylvania
Pennsylvania’s Greater Philadelphia corridor remains a biotech hotbed, housing over 1,200 life‑science firms including AstraZeneca, GSK and Johnson & Johnson. Eli Lilly announced a new injectable weight‑loss manufacturing plant in the Lehigh Valley, projected to create roughly 850 jobs by 2031....
Shape‑conformal 3D Frameworks Enable Full‑surface Neural Organoid Electrophysiology
If you’re interested in organoid biology and/or 3D bioelectronics, then check out our paper published today in Nature Biomedical Engineering, titled ‘Shape-conformal porous frameworks for full coverage of neural organoids and high-resolution electrophysiology,’ at https://t.co/Y7MzvRQKTm. This work introduces a technology...
Extending Scientific Rigor From Bench to Boardroom
Researchers who launch biotech startups often abandon evidence‑based decision‑making once they enter the boardroom, falling prey to technology myopia, base‑rate neglect, and confirmation bias. Their lack of formal training in commercialization, financial modeling, and competitive analysis amplifies these pitfalls, leading...
Scientists Develop the World’s Tiniest Wireless Brain Implant
Scientists at Cornell University have created a wireless brain implant so small it can sit on a grain of salt, yet still record and transmit neural activity. The device uses light‑based optics for power and data, eliminating bulky wires and...
On Its 15th Anniversary, Foresite Capital Looks Ahead
Foresite Capital marked its 15th anniversary by projecting a resurgence in biopharma venture capital, anticipating a year‑over‑year rise in financings and IPOs starting in 2026. The firm highlighted a surge to $149 billion in biopharma VC dollars in 2025 and a...
Reversing Nerve Cell Age to Combat ALS, Alzheimer’s
Super proud of Dr. Kelly Rich, senior postdoc in our lab who's pioneering nerve cell epigenetic age reversal to treat diseases such as ALS and Alzheimer's 🪨⭐️ https://open.spotify.com/episode/7nWkEH5li36oW9monEIG8B
INSM Projects 2026 Brinsupri Sales Minimum $1B
$INSM guides to 2026 Brinsupri sales of "at least $1B" in line with consensus. https://t.co/o7JhPKU3m1
Bone Marrow Cell Atlas Created for Improved Leukemia Research
Researchers at the Princess Máxima Center have produced the first multimodal single‑cell atlas of healthy pediatric bone marrow, profiling nearly 91,000 cells from nine donors aged two to 32. The atlas reveals that children’s marrow differs markedly from adult marrow in...
Cancer Immunotherapy Improved Using Targeted Stress Protein
Researchers at NYU Langone Health identified the integrated stress response protein lipocalin 2 (LCN2) as a key mediator that lets lung and pancreatic tumors evade immune attack. In mouse models, antibodies that block LCN2 restored T‑cell infiltration, slowed tumor growth, and...
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences reported its first commercial revenue of $86,000 from limited market release of the nPulse platform and Vibrance disposables. The company completed over 200 procedures across pilot programs and advanced multiple clinical studies, including FDA IDE clearance for the...
Host Control of Persistent Epstein–Barr Virus Infection
A multinational consortium investigated how host genetics influence persistent Epstein‑Barr virus (EBV) infection. Using large‑scale genome‑wide association studies across diverse cohorts, the team identified several host loci that modulate viral load and serostatus. Functional analyses linked these loci to immune...
Blood Test Holds Promise for Predicting when Alzheimer’s Symptoms Will Start
Researchers have developed a blood test that quantifies an abnormal form of tau protein, acting as a molecular clock to predict not only the likelihood of Alzheimer’s disease but also the timing of symptom onset. The study, published in Nature...
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals reported fourth‑quarter 2025 revenue of $3.2 billion, a 10% year‑over‑year increase, and full‑year revenue of $12 billion, up 9%. The company highlighted strong growth in its cystic fibrosis (CF) franchise, with 7% global expansion and double‑digit gains in the...
‘An AlphaFold 4’ – Scientists Marvel at DeepMind Drug Spin-Off’s Exclusive New AI
Isomorphic Labs unveiled IsoDDE, a proprietary AI engine touted as an “AlphaFold 4”‑level breakthrough in drug discovery. The 27‑page technical report claims the model outperforms AlphaFold 3, the open‑source Boltz‑2, and traditional physics‑based methods in predicting binding affinity and antibody‑protein interactions. Researchers...
Pharmacogenomics of Antiepileptic Drug Mood Stabilizer Treatment Response in Bipolar Disorder: A MoStGen Consortium Study
The Mood Stabilizer Genomics (MoStGen) Consortium analyzed 917 bipolar disorder patients to identify genetic predictors of response to antiepileptic mood stabilizers (AMS). Genome‑wide association studies revealed a robust association between lamotrigine response and variants in ROBO2, and a gene‑level signal...
A Transcriptional Program Associated with Neurotransmission in the Living Human Brain
Researchers from the Living Brain Project combined prefrontal cortex biopsies from 130 neurosurgical patients with intracranial recordings of dopamine, serotonin, and other neurotransmitters. Differential‑expression analyses of single‑nucleus and bulk RNA‑seq data revealed reproducible gene‑expression signatures that correlate with fast‑scan cyclic...
Exercise Mimetics as Unexplored Therapeutics for Treating Depression
The paper proposes exercise mimetics—pharmacological agents that imitate endurance training—as a novel class of antidepressants. While regular physical activity cuts depression risk by about 18 percent, adherence challenges limit its real‑world impact. Exercise mimetics activate muscle signaling pathways and alter the...
Ardelyx Inc (ARDX) Q4 2025 Earnings Call Transcript
Ardelyx reported Q4 2025 revenue of $110.3 million, driven primarily by a 92% year‑over‑year surge in IBSRELA sales to $78.2 million. The company raised its full‑year IBSRELA revenue guidance to $270‑$275 million and posted a net loss of roughly $1 million, while cash balances...
Insmed Inc (INSM) Q4 2025 Earnings Call Transcript
Insmed reported a $144.6 million net revenue for Brinsupri’s first full U.S. quarter, surpassing internal launch benchmarks. Management set a minimum $1 billion Brinsupri revenue target for 2026 and projected total company revenue to more than double 2025 levels, driven by continued...
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Transcript
Gilead Sciences reported total product sales of $28.9 billion for 2025, a 1% increase that topped the high end of its guidance. The HIV franchise generated $20.8 billion, up 6% overall and 10% on an underlying basis after removing the Medicare Part D...
Genentech’s Fenebrutinib Yields Positive Results in Phase III MS Trial
Genentech’s oral BTK inhibitor fenebrutinib met its primary endpoint in the Phase III FENtrepid trial for primary progressive multiple sclerosis, showing non‑inferiority to Ocrevus and a 12% risk reduction in confirmed disability progression. The drug also delivered a 26% lower risk...
![[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/3742a25a994e69efcb711edfa308902b.webp)
[Therapeutics] Adaptive Deep Brain Stimulation in Parkinson's Disease
Adaptive deep brain stimulation (aDBS) introduces real‑time modulation of stimulation amplitude by tracking subthalamic beta activity, shifting Parkinson's therapy from fixed to physiomarker‑guided. Clinical trials report superior motor improvement, reduced stimulation‑related side effects, and markedly lower energy consumption compared with...
Researchers Develop RNA-Activated Implant to Stimulate Nerve Regrowth After Spinal Cord Injury
Researchers at RCSI have created a 3‑D biomaterial implant that releases PTEN‑targeting siRNA to injured spinal cord neurons, reactivating growth pathways. The scaffold replicates spinal cord mechanical properties and delivers RNA particles directly to the lesion site, silencing the PTEN...
US Vaccine Policy Shift Boosts MRNA Stock Appeal
Macro: US vaccine-policy swing heightens regulatory risk; FDA will review Moderna’s flu shot. Key: public dispute, amended filing; decision by Aug 5. Risk: political oversight. Trade: Buy MRNA. — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
FDA Chief Warns U.S. Is Losing Ground to China in Early Drug Development, Calls for Faster Trial Approvals
FDA Commissioner Marty Makary warned that the United States is falling behind China in early‑stage drug development, citing slower Phase 1 trial volumes and cumbersome regulatory steps. He identified three primary bottlenecks—hospital contracting, ethical review processes, and the IND application workflow—that...
AI Automates Cytology, Streamlining Cell Pre‑Screening
AI automates cytology, which is a laborious, manual, human subjective task, for pre=screening cells for abnormalities and making initial diagnoses today @Nature https://t.co/ZI3F2pkMxE https://t.co/WsUcRjkHFN https://t.co/mdz1DM6xs7
Chemistry-Powered 'Breathing' Membrane Opens and Closes Tiny Pores on Its Own
Researchers at Osaka University have engineered a chemistry‑driven solid‑state membrane that autonomously opens and closes subnanometer pores by reversing the polarity of an applied voltage. The process relies on electrochemical precipitation to block the pore and dissolution to reopen it,...
Finalizing Top 100 Biotech VCs, Join 2026 Webinar
We're wrapping up the fact checking process for our annual Top 100 biotech VCs list and prepping for our companion webinar on VC investing in 2026. If this is a topic near and dear to your heart, be sure to...
SPT Labtech, BellBrook Labs Automate Screening for VPS4B ATPase Inhibitors for Cancer Drug Discovery
SPT Labtech and BellBrook Labs announced a joint effort to automate a high‑throughput, cell‑based assay for VPS4B ATPase inhibitors, pairing BellBrook’s Transcreener® ADP2 fluorescence‑polarization assay with SPT’s dragonfly® liquid‑handling system. The miniaturized platform operates in 384‑ and 1536‑well formats and...
Ultrasound-Jiggled Nanobubbles Can Crack Cancer's Collagen 'Fortress'
Researchers at Case Western Reserve University have shown that ultrasound‑activated nanobubbles can mechanically disrupt the dense collagen matrix surrounding solid tumors, creating a temporary “softening” effect that lasts several days. In a breast‑cancer model, the approach enabled deeper penetration of...
Anti-Aging Gene Therapy in Alzheimer’s and ALS with Klotho Neurosciences’ Dr. Joseph Sinkule — Episode 243
The Xtalks Life Science Podcast featured Joseph Sinkule, CEO of Klotho Neurosciences, discussing the company’s secreted α‑Klotho gene therapy platform aimed at age‑related neurodegenerative diseases such as Alzheimer’s, ALS and Parkinson’s. Klotho leverages a patented anti‑aging gene to develop cell‑ and...
Quantum-Level Effects in Biology: Weak Magnetic Fields and Isotopes Can Alter Cell Protein Structures
University of Waterloo researchers demonstrated that weak magnetic fields and isotopic substitution can alter the structure of cellular proteins, specifically tubulin polymerization, in a quantum‑consistent manner. Published in Science Advances, the study bridges structural biology, biophysics, and quantum biology, revealing...
Conversational AI Unlocks Hidden Value in Scientific Literature
So cool to see the focus on really mining the scientific literature from @EdisonSci — it’s where a ton of valuable information is waiting and having models conversant in it is a big deal 👏👏👏
Brain’s Venous Sinuses Patrol Immune Cells and Drain Fluid
What's ruffling? Large veins interfacing the skull (venous sinuses) that patrol immune cells and help drain the brain https://t.co/WsML3Jd1yA
Pediatric Myopia Drug Is Latest In String Of Unexpected FDA Rejections
The FDA has rejected a pediatric myopia drug, citing a lack of substantial evidence for its efficacy. Pediatric ophthalmologists argue the drug, already used in compounded form, effectively slows myopia progression in children. The decision follows a series of recent,...
FDA Backtracks On Moderna mRNA Flu Vaccine Refusal, Sets Aug. 5 Review Deadline
The U.S. Food and Drug Administration has reversed its earlier decision to decline a review of Moderna's mRNA influenza vaccine candidate. Following a Type A meeting with the company, the agency set an August 5, 2026 deadline for completing its evaluation. The...